DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy

被引:18
作者
Thijssen, Peter E. [1 ]
Balog, Judit [1 ]
Yao, Zizhen [2 ]
Tan Phat Pham [1 ]
Tawil, Rabi [3 ]
Tapscott, Stephen J. [2 ]
Van der Maarel, Silvere M. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
[2] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA
[3] Univ Rochester, Med Ctr, Dept Neurol, Neuromuscular Dis Unit, Rochester, NY 14642 USA
来源
SKELETAL MUSCLE | 2014年 / 4卷
基金
美国国家卫生研究院;
关键词
Facioscapulohumeral muscular dystrophy (FSHD); FRG2; D4Z4; DUX4; Promoter; Transcription factor; REGION GENE-1; FSHD REGION; CHROMATIN-STRUCTURE; DNA REARRANGEMENTS; CANDIDATE GENE; EXPRESSION; LOCUS; PATIENT; PROTEIN; MODEL;
D O I
10.1186/2044-5040-4-19
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: The most common form of facioscapulohumeral muscular dystrophy (FSHD) is caused by a genetic contraction of the polymorphic D4Z4 macrosatellite repeat array in the subtelomeric region of chromosome 4q. In some studies, genes centromeric to the D4Z4 repeat array have been reported to be over-expressed in FSHD, including FRG1 and FRG2, presumably due to decreased long-distance repression by the shorter array through a mechanism similar to position-effect variegation. Differential regulation of FRG1 in FSHD has never been unequivocally proven, however, FRG2 has been reproducibly shown to be induced in primary FSHD-derived muscle cells when differentiated in vitro. The molecular function of FRG2 and a possible contribution to FSHD pathology remain unclear. Recent evidence has identified the mis-expression of DUX4, located within the D4Z4 repeat unit, in skeletal muscle as the cause of FSHD. DUX4 is a double homeobox transcription factor that has been shown to be toxic when expressed in muscle cells. Methods: We used a combination of expression analysis by qRT/PCR and RNA sequencing to determine the transcriptional activation of FRG2 and DUX4. We examined this in both differentiating control and FSHD derived muscle cell cultures or DUX4 transduced control cell lines. Next, we used ChIP-seq analysis and luciferase reporter assays to determine the potential DUX4 transactivation effect on the FRG2 promoter. Results: We show that DUX4 directly activates the expression of FRG2. Increased expression of FRG2 was observed following expression of DUX4 in myoblasts and fibroblasts derived from control individuals. Moreover, we identified DUX4 binding sites at the FRG2 promoter by chromatin immunoprecipitation followed by deep sequencing and confirmed the direct regulation of DUX4 on the FRG2 promoter by luciferase reporter assays. Activation of luciferase was dependent on both DUX4 expression and the presence of the DUX4 DNA binding motifs in the FRG2 promoter. Conclusion: We show that the FSHD-specific upregulation of FRG2 is a direct consequence of the activity of DUX4 protein rather than representing a regional de-repression secondary to fewer D4Z4 repeats.
引用
收藏
页数:9
相关论文
共 36 条
  • [11] Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
    Jones, Takako I.
    Parilla, Megan
    Jones, Peter L.
    PLOS ONE, 2016, 11 (03):
  • [12] p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy
    Bosnakovski, Darko
    Gearhart, Micah D.
    Toso, Erik A.
    Recht, Olivia O.
    Cucak, Anja
    Jain, Abhinav K.
    Barton, Michelle C.
    Kyba, Michael
    DISEASE MODELS & MECHANISMS, 2017, 10 (10) : 1211 - 1216
  • [13] Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
    Chen, Jennifer C. J.
    King, Oliver D.
    Zhang, Yuanfan
    Clayton, Nicholas P.
    Spencer, Carrie
    Wentworth, Bruce M.
    Emerson, Charles P., Jr.
    Wagner, Kathryn R.
    MOLECULAR THERAPY, 2016, 24 (08) : 1405 - 1411
  • [14] Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments
    Duranti, Elisa
    Villa, Chiara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [15] DUX4 Transcript Knockdown with Antisense 2′-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy
    Lim, Kenji Rowel Q.
    Bittel, Adam
    Maruyama, Rika
    Echigoya, Yusuke
    Quynh Nguyen
    Huang, Yiqing
    Dzierlega, Kasia
    Zhang, Aiping
    Chen, Yi-Wen
    Yokota, Toshifumi
    MOLECULAR THERAPY, 2021, 29 (02) : 848 - 858
  • [16] A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
    Feng, Qing
    Snider, Lauren
    Jagannathan, Sujatha
    Tawil, Rabi
    van der Maarel, Silvere M.
    Tapscott, Stephen J.
    Bradley, Robert K.
    ELIFE, 2015, 4
  • [17] A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
    Mariot, Virginie
    Joubert, Romain
    Marsollier, Anne-Charlotte
    Hourde, Christophe
    Voit, Thomas
    Dumonceaux, Julie
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 22 : 1191 - 1199
  • [18] A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy
    Jones, Takako
    Jones, Peter L.
    PLOS ONE, 2018, 13 (02):
  • [19] Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy
    Vangipurapu, Rajanikanth
    Oliva, Jonathan
    Fox, Amelia
    Sverdrup, Francis M.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [20] Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
    Ganassi, Massimo
    Figeac, Nicolas
    Reynaud, Magalie
    Ortuste Quiroga, Huascar Pedro
    Zammit, Peter S. S.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10